

Art Unit: 1643

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kate Berezutskaya on July 21, 2008.

The application has been amended as follows:

Claim 28 has been amended as follows:

The phrase "contacting the target cell" has been replaced by --contacting a target cell expressing PSMA---.

Claim 46 has been amended as follows:

9-11-8 MB
The phrase "wherein ~~the~~ ^{said} targeting specific protease is PSMA" has been replaced by the phrase---wherein the inactivator is cleaved from the procytotoxin by PSMA---.

Claim 56 has been replaced with the following:

56. The method of claim 55 wherein said targeting molecule is selected from the group consisting of a molecule that targets neovasculature and an antibody.

Claim 58 has been replaced with the following:

58. The method of claim 28 wherein the target cell is a prostate cancer cell.

Claim 59 has been canceled.

Claim 60 has been replaced with the following: